Mineralys Therapeutics Files Routine 8-K, Confirms Nasdaq Listing
Ticker: MLYS · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1933414
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, administrative
TL;DR
**Mineralys Therapeutics filed a routine 8-K, no major news.**
AI Summary
Mineralys Therapeutics, Inc. filed an 8-K on January 4, 2024, to report general corporate information and confirm its status as a publicly traded company on The Nasdaq Stock Market LLC under the trading symbol MLYS. This filing primarily serves to update administrative details and confirm compliance with SEC regulations, rather than announcing a specific material event. For investors, this filing is a routine update, indicating no immediate significant changes that would directly impact the stock's value, but it confirms the company's ongoing operational and reporting status.
Why It Matters
This filing is a standard administrative update, confirming Mineralys Therapeutics' compliance and listing on Nasdaq, which is important for maintaining investor confidence and market access.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing with no material changes or disclosures that would introduce new risks.
Analyst Insight
This filing is routine and does not present new information warranting immediate action. Investors should continue to monitor for more substantive filings, such as earnings reports or material event disclosures.
Key Numbers
- $0.0001 — par value per share (the stated par value of Mineralys Therapeutics' Common Stock)
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where the company's common stock is registered
- MLYS (company) — the trading symbol for Mineralys Therapeutics, Inc. Common Stock
- January 4, 2024 (date) — the date of the earliest event reported and filing date
- $0.0001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Mineralys Therapeutics will continue to maintain its listing on The Nasdaq Stock Market LLC. (Mineralys Therapeutics, Inc.) — high confidence, target: 2025-01-04
FAQ
What is the purpose of this specific 8-K filing by Mineralys Therapeutics, Inc.?
This 8-K filing, dated January 4, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. It primarily serves to report general corporate information, including the company's registration on The Nasdaq Stock Market LLC under the trading symbol MLYS, and to confirm its status as a publicly traded entity.
What is the trading symbol and exchange for Mineralys Therapeutics, Inc. Common Stock?
The Common Stock, par value $0.0001 per share, of Mineralys Therapeutics, Inc. trades under the symbol MLYS on The Nasdaq Stock Market LLC, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the earliest event reported date in this 8-K filing?
The 'Date of report (Date of earliest event reported)' is January 4, 2024, as specified on the cover page of the Form 8-K.
What is the state of incorporation for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. is incorporated in Delaware, as indicated under the 'State or other jurisdiction of incorporation or organization' on the cover page of the filing.
Does this 8-K filing indicate any changes in directors or officers, or new compensatory arrangements?
While the 'ITEM INFORMATION' section lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', the body of this specific 8-K filing (0001933414-24-000002.txt) does not contain any details or disclosures regarding such events. It appears to be a placeholder or a general item description for the form type, with no specific event reported under this item in the provided text.
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-04 16:10:49
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Marke
Filing Documents
- mlys-20240104.htm (8-K) — 28KB
- mlys202401048kex991.htm (EX-99) — 12KB
- image_0a.jpg (GRAPHIC) — 5KB
- 0001933414-24-000002.txt ( ) — 183KB
- mlys-20240104.xsd (EX-101.SCH) — 2KB
- mlys-20240104_lab.xml (EX-101.LAB) — 25KB
- mlys-20240104_pre.xml (EX-101.PRE) — 13KB
- mlys-20240104_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 4, 2024 , the Company issued a press release announcing the appointment of Minji Kim, Ph.D. as Chief Business Officer. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued on January 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 4, 2024 MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary